Innoveren Scientific Stock Price, News & Analysis
Company Description
Innoveren Scientific (OTC Link: IVRN) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $932.0.
IVRN stock has declined 20.0% over the past year. Shares last traded at $0.0004.
This page provides a comprehensive overview of IVRN stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Innoveren Scientific (IVRN) stock last traded at $0.0004. Over the past 12 months, the stock has lost 20.0%. At a market capitalization of $932.0, IVRN is classified as a micro-cap stock with approximately 712.7K shares outstanding.
Latest News
Innoveren Scientific has 2 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 0 with negative movement. View all IVRN news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Innoveren Scientific (IVRN) currently stands at 5 shares, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 99.1%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Innoveren Scientific (IVRN) currently stands at 5.0 days, down 99.5% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 252.1% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
IVRN Company Profile & Sector Positioning
Innoveren Scientific (IVRN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing IVRN often look at related companies in the same sector, including Effector Therapeutics Inc (EFTR), Gritstone Bio Inc (GRTSQ), Eloxx Pharmaceut (ELOX), Renovacare (RCAR), and Ampio Pharma (AMPE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IVRN's relative position within its industry.